Standard dose of effervescent progesterone vaginal tablet for luteal phase support in frozen embryo transfer cycle

Standard dose of effervescent progesterone vaginal tablet for luteal phase support in frozen embryo transfer cycle - SHIFT study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021983

Enrollment

400

Registered

2016-04-19

Start date

2015-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Patients who have given written informed consent to participate in this study 2) Patients who underwent IVF-ICSI to obtain autologous frozen embryo 3) Patients who will undergo the frozen embryo transfer in artificial cycles.

Exclusion criteria

Exclusion criteria: Patients who had a history of oversensitivity, abnormal uterine bleeding of undetermined origin, missed abortion, ectopic pregnancy, severe hepatic disorder, breast cancer, genital cancer and porphyria, and are under breast-feeding.

Design outcomes

Primary

Measure	Time frame
ongoing pregnancy rate (six weeks after administration of the drug)	—

Secondary

Measure	Time frame
1) hCG positive rate 2) clinical pregnancy rate 3) safety information 4) withdrawal rate 5) relationship between ongoing pregnancy rate and age or serum progesterone level	—

Countries

Japan

Contacts

Public ContactTOSHIHIRO FUJIWARA

Sanno Hospital Center for Human Reproduction and Gynecologic Endoscopy

metsugi@iuhw.ac.jp03-3402-3151

Outcome results